皮膚放射線障害薬の世界市場:規模・現状・予測2019-2025

【英語タイトル】Global Cutaneous Radiation Injury Drug Market Size, Status and Forecast 2019-2025

QYResearchが出版した調査資料(QYR20FB13976)・商品コード:QYR20FB13976
・発行会社(調査会社):QYResearch
・発行日:2019年12月(※2024年版があります。お問い合わせください)
・ページ数:90
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
※当調査レポートでは、皮膚放射線障害薬の世界市場について調査・分析し、皮膚放射線障害薬の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別(経口薬、外用薬)、用途別(病院薬局、オンライン薬局、小売薬局)、地域別(北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米)に区分して市場規模を算出しました。


・レポートの概要
・世界の皮膚放射線障害薬市場動向
・主要企業別マーケットシェア
・皮膚放射線障害薬の種類別市場規模2014-2019
(経口薬、外用薬)
・皮膚放射線障害薬の用途別市場規模2014-2019
(病院薬局、オンライン薬局、小売薬局)
・皮膚放射線障害薬の北米市場:主要企業・種類別/用途別市場規模
・皮膚放射線障害薬のヨーロッパ市場:主要企業・種類別/用途別市場規模
・皮膚放射線障害薬の中国市場:主要企業・種類別/用途別市場規模
・皮膚放射線障害薬の日本国内市場:主要企業・種類別/用途別市場規模
・皮膚放射線障害薬の東南アジア市場:主要企業・種類別/用途別市場規模
・皮膚放射線障害薬のインド市場:主要企業・種類別/用途別市場規模
・皮膚放射線障害薬の中南米市場:主要企業・種類別/用途別市場規模
・主要企業のプロフィール
(Merck、Novartis、Johnson & Johnson、Pfizer、Amgen、Roche、Eli Lily、AstraZeneca、Teva)
・皮膚放射線障害薬の市場規模予測2019-2025
(種類別、用途別、地域別市場予測)
・アナリストの観点・結論
...
【レポートの概要】

Cutaneous radiation injury occurs on a functional, cellular, and gross level. Radiation therapy is the major modality in the management of cancer treatment along with the surgery and chemotherapy. Most common side effect of the radiation is the acute skin reaction which usually range from mild to confluent moist desquamation.In 2018, the global Cutaneous Radiation Injury Drug market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Cutaneous Radiation Injury Drug status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cutaneous Radiation Injury Drug development in North America, Europe and Asia-Pacific.

The key players covered in this study
Merck
Novartis
Johnson & Johnson
Pfizer
Amgen
Roche
Eli Lily
AstraZeneca
Teva

Market segment by Type, the product can be split into
Oral Drug
Topical Drug

Market segment by Application, split into
Hospital Pharmacies
Online Pharnacies
Retail Pharmacies

Market segment by Regions/Countries, this report covers
North America
Europe
Asia-Pacific

The study objectives of this report are:
To analyze global Cutaneous Radiation Injury Drug status, future forecast, growth opportunity, key market and key players.
To present the Cutaneous Radiation Injury Drug development in North America, Europe and Asia-Pacific.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Cutaneous Radiation Injury Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Cutaneous Radiation Injury Drug Market Size Growth Rate by Type (2014-2025)
1.4.2 Oral Drug
1.4.3 Topical Drug
1.5 Market by Application
1.5.1 Global Cutaneous Radiation Injury Drug Market Share by Application (2019-2025)
1.5.2 Hospital Pharmacies
1.5.3 Online Pharnacies
1.5.4 Retail Pharmacies
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Cutaneous Radiation Injury Drug Market Size
2.2 Cutaneous Radiation Injury Drug Growth Trends by Regions
2.2.1 Cutaneous Radiation Injury Drug Market Size by Regions (2019-2025)
2.2.2 Cutaneous Radiation Injury Drug Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players
3.1 Cutaneous Radiation Injury Drug Market Size by by Players
3.1.1 Global Cutaneous Radiation Injury Drug Revenue by by Players (2014-2019)
3.1.2 Global Cutaneous Radiation Injury Drug Revenue Market Share by by Players (2014-2019)
3.1.3 Global Cutaneous Radiation Injury Drug Market Concentration Ratio (CR5 and HHI)
3.2 Cutaneous Radiation Injury Drug Key Players Head office and Area Served
3.3 Key Players Cutaneous Radiation Injury Drug Product/Solution/Service
3.4 Date of Enter into Cutaneous Radiation Injury Drug Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Cutaneous Radiation Injury Drug Market Size by Type (2014-2019)
4.2 Global Cutaneous Radiation Injury Drug Market Size by Application (2014-2019)

5 North America
5.1 North America Cutaneous Radiation Injury Drug Market Size (2014-2019)
5.2 Cutaneous Radiation Injury Drug Key Players in North America
5.3 North America Cutaneous Radiation Injury Drug Market Size by Type
5.4 North America Cutaneous Radiation Injury Drug Market Size by Application

6 Europe
6.1 Europe Cutaneous Radiation Injury Drug Market Size (2014-2019)
6.2 Cutaneous Radiation Injury Drug Key Players in Europe
6.3 Europe Cutaneous Radiation Injury Drug Market Size by Type
6.4 Europe Cutaneous Radiation Injury Drug Market Size by Application

7 Asia-Pacific
7.1 Asia-Pacific Cutaneous Radiation Injury Drug Market Size (2014-2019)
7.2 Cutaneous Radiation Injury Drug Key Players in Asia-Pacific
7.3 Asia-Pacific Cutaneous Radiation Injury Drug Market Size by Type
7.4 Asia-Pacific Cutaneous Radiation Injury Drug Market Size by Application

8 International Players Profiles
8.1 Merck
8.1.1 Merck Company Details
8.1.2 Company Description and Business Overview
8.1.3 Cutaneous Radiation Injury Drug Introduction
8.1.4 Merck Revenue in Cutaneous Radiation Injury Drug Business (2014-2019))
8.1.5 Merck Recent Development
8.2 Novartis
8.2.1 Novartis Company Details
8.2.2 Company Description and Business Overview
8.2.3 Cutaneous Radiation Injury Drug Introduction
8.2.4 Novartis Revenue in Cutaneous Radiation Injury Drug Business (2014-2019)
8.2.5 Novartis Recent Development
8.3 Johnson & Johnson
8.3.1 Johnson & Johnson Company Details
8.3.2 Company Description and Business Overview
8.3.3 Cutaneous Radiation Injury Drug Introduction
8.3.4 Johnson & Johnson Revenue in Cutaneous Radiation Injury Drug Business (2014-2019)
8.3.5 Johnson & Johnson Recent Development
8.4 Pfizer
8.4.1 Pfizer Company Details
8.4.2 Company Description and Business Overview
8.4.3 Cutaneous Radiation Injury Drug Introduction
8.4.4 Pfizer Revenue in Cutaneous Radiation Injury Drug Business (2014-2019)
8.4.5 Pfizer Recent Development
8.5 Amgen
8.5.1 Amgen Company Details
8.5.2 Company Description and Business Overview
8.5.3 Cutaneous Radiation Injury Drug Introduction
8.5.4 Amgen Revenue in Cutaneous Radiation Injury Drug Business (2014-2019)
8.5.5 Amgen Recent Development
8.6 Roche
8.6.1 Roche Company Details
8.6.2 Company Description and Business Overview
8.6.3 Cutaneous Radiation Injury Drug Introduction
8.6.4 Roche Revenue in Cutaneous Radiation Injury Drug Business (2014-2019)
8.6.5 Roche Recent Development
8.7 Eli Lily
8.7.1 Eli Lily Company Details
8.7.2 Company Description and Business Overview
8.7.3 Cutaneous Radiation Injury Drug Introduction
8.7.4 Eli Lily Revenue in Cutaneous Radiation Injury Drug Business (2014-2019)
8.7.5 Eli Lily Recent Development
8.8 AstraZeneca
8.8.1 AstraZeneca Company Details
8.8.2 Company Description and Business Overview
8.8.3 Cutaneous Radiation Injury Drug Introduction
8.8.4 AstraZeneca Revenue in Cutaneous Radiation Injury Drug Business (2014-2019)
8.8.5 AstraZeneca Recent Development
8.9 Teva
8.9.1 Teva Company Details
8.9.2 Company Description and Business Overview
8.9.3 Cutaneous Radiation Injury Drug Introduction
8.9.4 Teva Revenue in Cutaneous Radiation Injury Drug Business (2014-2019)
8.9.5 Teva Recent Development

9 Market Forecast 2019-2025
9.1 Market Size Forecast by Product (2019-2025)
9.2 Market Size Forecast by Application (2019-2025)
9.3 Market Size Forecast by Regions
9.4 North America
9.5 Europe
9.6 Asia-Pacific

10 Analyst’s Viewpoints/Conclusions

11 Appendix
11.1 Research Methodology
11.1.1 Methodology/Research Approach
11.1.1.1 Research Programs/Design
11.1.1.2 Market Size Estimation
11.1.1.3 Market Breakdown and Data Triangulation
11.1.2 Data Source
11.1.2.1 Secondary Sources
11.1.2.2 Primary Sources
11.2 Disclaimer
11.3 Author Details



【掲載企業】

Merck、Novartis、Johnson & Johnson、Pfizer、Amgen、Roche、Eli Lily、AstraZeneca、Teva

★調査レポート[皮膚放射線障害薬の世界市場:規模・現状・予測2019-2025] (コード:QYR20FB13976)販売に関する免責事項を必ずご確認ください。
★調査レポート[皮膚放射線障害薬の世界市場:規模・現状・予測2019-2025]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆